Rivaroxaban 10 MG Oral Tablet [Xarelto]
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bariatric Surgery
Conditions
Bariatric Surgery
Trial Timeline
Jul 19, 2018 → Dec 31, 2023
NCT ID
NCT03522259About Rivaroxaban 10 MG Oral Tablet [Xarelto]
Rivaroxaban 10 MG Oral Tablet [Xarelto] is a phase 2 stage product being developed by Bayer for Bariatric Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT03522259. Target conditions include Bariatric Surgery.
What happened to similar drugs?
1 of 3 similar drugs in Bariatric Surgery were approved
Approved (1) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03522259 | Phase 2 | Completed |
Competing Products
9 competing products in Bariatric Surgery
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MBX 1416 (INN imapextide) | MBX Biosciences | Phase 2 | 36 |
| MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C) | MBX Biosciences | Phase 1 | 23 |
| Duloxetine | Eli Lilly | Phase 3 | 40 |
| Esomeprazole | AstraZeneca | Approved | 43 |
| rivaroxaban 20 mg once daily 8 days | Bayer | Phase 1 | 26 |
| Pasireotide Diaspartate | Recordati | Phase 2 | 36 |
| Avexitide | Amylyx Pharmaceuticals | Phase 3 | 38 |
| glucagon | Xeris Pharmaceuticals | Phase 1/2 | 26 |
| ARD-101 | Aardvark Therapeutics | Phase 2 | 25 |